Document Type : Original Article
Authors
1 Department of Microbiology, Mayo Institute of Medical Sciences, Barabanki, Uttar Pradesh, India
2 Department of Microbiology, Gold Field Institute of Medical Sciences and Research, Faridabad, Haryana, India
Abstract
Objective: There is an increased prevalence of extended‑spectrum beta‑lactamase producing
Klebsiella pneumoniae (ESBL‑KP) worldwide including India, which is a major concern
for the clinicians, especially in intensive care units and pediatric patients. This study aims to
determine the prevalence of ESBL‑KP and antimicrobial sensitivity profile to plan a proper
hospital infection control program to prevent the spread of resistant strains.
Methods: KP isolates obtained from various clinical samples were evaluated to detect the
production of ESBL by phenotypic methods. Antimicrobial susceptibility profile was also
determined of all the isolates.
Findings: Of 223 nonduplicate isolates of K. pneumoniae, 114 (51.1%) were ESBL producer
and antimicrobial susceptibility profile showed the isolates were uniformly sensitive to
imipenem and highly susceptible to beta‑lactamase inhibitor combination drugs(67–81%) and
aminoglycosides (62–76%), but less susceptible to third generation cephalosporins (14–24%)
and non‑β‑lactam antibiotics such as nitrofurantoin (57%), fluoroquinolones (29–57%),
piperacillin (19–23%), and aztreonam (15–24%).
Conclusion: This study found that beta‑lactamase inhibitor combinations are effective
in treatment of such infections due to ESBL‑KP thus these drugs should be a part of the
empirical therapy and carbapenems should be used when the antimicrobial susceptibility
tests report resistance against inhibitors combinations.
Keywords
gram‑negative bacteria. N Engl J Med 2010;362:1804‑13.
2. ZarkotouO, Pournaras S, TseliotiP, Dragoumanos V, Pitiriga V,
Ranellou K, et al. Predictors of mortality in patients with
bloodstream infections caused by KPC‑producing Klebsiella
pneumoniae and impact of appropriate antimicrobial
treatment. Clin Microbiol Infect 2011;17:1798‑803.
3. Christian NA, Roye‑Green K, Smikle M. Molecular
epidemiology of multidrug resistant extended spectrum
beta‑lactamase producing Klebsiella pneumoniae at a
Jamaican hospital, 2000‑2004. BMC Microbiol 2010;10:27.
4. Filippa N, Carricajo A, Grattard F, Fascia P, El Sayed F,
Defilippis JP, et al. Outbreak of multidrug‑resistant Klebsiella
pneumoniae carrying qnrB1 and blaCTX‑M15 in a French
intensive care unit. Ann Intensive Care 2013;3:18.
5. Bush K, Jacoby GA. Updated functional classification
of beta‑lactamases. Antimicrob Agents Chemother
2010;54:969‑76.
6. Demirdag K, Hosoglu S. Epidemiology and risk factors for
ESBL‑producing Klebsiella pneumoniae: A case control study.
J Infect Dev Ctries 2010;4:717‑22.
7. Tuon FF, Kruger M, Terreri M, Penteado‑Filho SR, Gortz L.
Klebsiella ESBL bacteremia‑mortality and risk factors. Braz J
Infect Dis 2011;15:594‑8.
8. Clinical Laboratory Standard Institute. Performance Standards
for Antimicrobial Susceptibility Testing; Twenty‑Second
Informational Supplement. Vol. 33. Wayne, Pennsylvania,
USA: Clinical Laboratory Standard Institute; 2013.
9. Babypadmini S, Appalaraju B. Extended spectrum ‑lactamases
in urinary isolates of Escherichia coli and Klebsiella
pneumoniae – Prevalence and susceptibility pattern in a
tertiary care hospital. Indian J Med Microbiol 2004;22:172‑4.
10. Menon T, Bindu D, Kumar CP, Nalini S, Thirunarayan MA.
Comparison of double disc and three dimensional methods
to screen for ESBL producers in a tertiary care hospital. Indian
J Med Microbiol 2006;24:117‑20.
11. Goossens H, Grabein B. Prevalence and antimicrobial
susceptibility data for extended‑spectrum beta‑lactamase‑ and
AmpC‑producing Enterobacteriaceae from the MYSTIC
Program in Europe and the United States (1997‑2004). Diagn
Microbiol Infect Dis 2005;53:257‑64.
12. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM,
PollockDA, et al. NHSN annual update: Antimicrobial‑resistant
pathogens associated with healthcare‑associated infections:
Annual summary of data reported to the National Healthcare
Safety Network at the Centers for Disease Control and
Prevention, 2006‑2007. Infect Control Hosp Epidemiol
2008;29:996‑1011.
13. Harada Y, Morinaga Y, Yamada K, Migiyama Y, Nagaoka K,
Uno N, et al. Clinical and molecular epidemiology of
extended‑spectrum β‑lactamase producing Klebsiella
pneumoniae and Escherichia coli in a Japanese tertiary
hospital. J Med Microbiol Diagn 2013;2:127.
14. Kim MH, Lee HJ, Park KS, Suh JT. Molecular characteristics
of extended spectrum beta‑lactamases in Escherichia coli and
Klebsiella pneumoniae and the prevalence of qnr in Extended
spectrum beta‑lactamase isolates in a tertiary care hospital in
Korea. Yonsei Med J 2010;51:768‑74.
15. Kuo KC, Shen YH, Hwang KP. Clinical implications and
risk factors of extended‑spectrum beta‑lactamase‑producing
Klebsiella pneumoniae infection in children: A case‑control
retrospective study in a medical center in Southern Taiwan.
J Microbiol Immunol Infect 2007;40:248‑54.
16. Ho PL, Tsang DN, Que TL, Ho M, Yuen KY. Comparison
of screening methods for detection of extended‑spectrum
beta‑lactamases and their prevalence among Escherichia coli
and Klebsiella species in Hong Kong. APMIS 2000;108:237‑40.
17. Agrawal P, GhoshAN, Kumar S, Basu B, Kapila K. Prevalence
of extended‑spectrum beta‑lactamases among Escherichia coli
and Klebsiella pneumoniae isolates in a tertiary care hospital.
Indian J Pathol Microbiol 2008;51:139‑42.
18. Aruna K, Mobashshera T. Prevalence of extended spectrum
beta‑lactamase production among uropathogens in South
Mumbai and its antibiogram pattern. EXCLI J 2012;11:363‑72.
19. Dalela G. Prevalence of extended spectrum beta
lactamase (ESBL) producers among gram‑negative bacilli
from various clinical isolates in a tertiary care hospital at
Jhalawar, Rajasthan, India. J Clin Diagn Res 2012;6:182‑7.
20. Abhilash KP, Veeraraghavan B, Abraham OC. Epidemiology
and outcome of bacteremia caused by extended spectrum
beta‑lactamase (ESBL)‑producing Escherichia coli and
Klebsiella spp. in a tertiary care teaching hospital in South
India. J Assoc Physicians India 2010;58 Suppl: 13‑7.
21. Sarojamma V, Ramakrishna V. Prevalence of ESBL‑Producing Klebsiella pneumoniae isolates in tertiary care hospital. ISRN
Microbiol 2011;2011:318348.
22. Gupta V, Singla N, Chander J. Detection of ESBLs using third
and fourth generation cephalosporins in double disc synergy
test. Indian J Med Res 2007;126:486‑7.
23. Ananthan S, Subha A. Cefoxitin resistance mediated by loss
of a porin in clinical strains of Klebsiella pneumoniae and
Escherichia coli. Indian J Med Microbiol 2005;23:20‑3.
24. Chandramohan L, Revell PA. Prevalence and molecular
characterization of extended‑spectrum‑ß‑lactamase‑producing
Enterobacteriaceae in a pediatric patient population.
Antimicrob Agents Chemother 2012;56:4765‑70.
25. Goyal A, Prasad KN, Prasad A, Gupta S, Ghoshal U,
AyyagariA. Extended spectrum beta‑lactamases in Escherichia
coli & Klebsiella pneumoniae & associated risk factors. Indian
J Med Res 2009;129:695‑700.
26. SomilyAM, Habib HA, Absar MM, Arshad MZ, Manneh K, Al
Subaie SS, et al. ESBL‑producing Escherichia coli and Klebsiella
pneumoniae at a tertiary care hospital in Saudi Arabia. J Infect
Dev Ctries 2014;8:1129‑36.
27. Maina D, Makau P, Nyerere A, Revathi G. Antimicrobial
resistance patterns in extended‑spectrum β‑lactamase
producing Escherichia coli and Klebsiella pneumoniae isolates
in a private tertiary hospital, Kenya. Microbiol Discov 2013;1:5.
)